Virbac (CHIX:VIRPP) Beta: 0.3647 (As of Jun. 26, 2026)


CHIX:VIRPP Virbac SA CHIX:VIRPP
95 GF Score
Price €354.25
GF Value €384.87
! 2 Warning Signs
View Full Analysis

What is Virbac Beta?

Virbac CHIX:VIRPP 95 Beta is 0.3647 as of Jun. 26, 2026. GuruFocus rates CHIX:VIRPP with a GF Score™ of 95/100 and a GF Value™ of €384.87. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Virbac's Beta is 0.3647.


Virbac  (CHIX:VIRPp) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Virbac Beta Related Terms


Virbac Beta Historical Data

* Premium members only.

The historical data trend for Virbac's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Beta Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.05 0.42 0.23

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.15 0.42 0.43 0.23

CHIX:VIRPP vs LLY, JNJ, ABBV: Beta Comparison

For the Drug Manufacturers - General subindustry, Virbac's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virbac Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Virbac's Beta distribution charts can be found below:

* The bar in red indicates where Virbac's Beta falls into.


CHIX:VIRPP
95GF Score
Virbac SA CHIX:VIRPP
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3647 mean?
Virbac (CHIX:VIRPP) has a Beta of 0.3647 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Virbac and its competitors.
Is Virbac's Beta too high?
Virbac's current Beta is 0.3647. Overall, Virbac has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Virbac's Beta compare to LLY and JNJ?
Virbac's Beta of 0.3647 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Virbac and its competitors. Virbac's current Beta is 0.3647. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Virbac (CHIX:VIRPP) has a current Beta of 0.3647. The stock's GF Value™ is €384.87, compared to a current price of €354.25 — trading 8% below its estimated fair value. The current Beta is 0.3647. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Beta is 0.3647 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €354.25 is trading 8% below its estimated GF Value™ of €384.87.

Key valuation signals for CHIX:VIRPP:

  • Beta: 0.3647
  • GF Value™: €384.87 vs. price of €354.25 (8% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score

Get the complete analysis for CHIX:VIRPP

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€354.25
Price
€384.87
GF Value